References of "Masereel, B."
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNovel inhibitors of the sodium-calcium exchanger: benzene ring analogues of N-guanidino substituted amiloride derivatives
Rogister, F.; Laeckmann, D.; Plasman, P.-O. et al

in European Journal of Medicinal Chemistry (2001), 36

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood
De Leval, X.; Delarge, J.; Devel, P. et al

in Prostaglandins, Leukotrienes, and Essential Fatty Acids (2001), 64

Detailed reference viewed: 11 (0 ULg)
Peer Reviewed
See detailPharmacology of the Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor Bm-531
Dogné, J. M.; Rolin, S.; de Leval, X. et al

in Cardiovascular Drug Reviews (2001), 19(2, Summer), 87-96

BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor. Indeed, its ... [more ▼]

BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor. Indeed, its affinity for human washed platelet TXA2 receptors labeled with [3H]SQ-29548 (IC50 = 0.0078 microM) is higher than sulotroban (IC50 = 0.93 microM) and SQ-29548 (IC50 = 0.021 microM). Moreover, BM-531 is characterized by a potent antiaggregatory property. Indeed, on one hand, in human citrated platelet-rich plasma BM-531 prevents platelet aggregation induced by arachidonic acid (600 microM) (ED100 = 0.125 microM), U-46619, a stable TXA2 agonist (1 microM) (ED50 = 0.482 microM) or collagen (1 microgram/mL) (percentage of inhibition: 42.9% at 10 microM) and inhibits the second wave of ADP (2 microM)-induced aggregation. On the other hand, when BM-531 is incubated in whole blood from healthy donors, the closure time measured by the recently developed platelet function analyser (PFA-100) is significantly prolonged. In addition, at the concentrations of 10 and 1 microM, BM-531 totally prevents the production of TXB2 by human platelets activated by arachidonic acid. Finally, at 10 microM, BM-531 significantly prevents rat fundus contractions induced by U-46619 but not by prostacyclin. These results suggest that BM-531, which is devoid of the diuretic property of torasemide, can be regarded as a promising antiplatelet agent. [less ▲]

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailInhibition of cellular invasion by 3-chlorophenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-carboxylate
Kempen, I.; Pochet, L.; Papapostulu, D. et al

Poster (2000, September)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailOxobenzopyran derivatives as thrombin inhibitors
Bourdel, F.; Lacan, F.; Doucet, C. et al

Poster (2000, September)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailSpecific inhibitors of human leukocyte elastase
Reboud-Ravaux, M.; Pochet, L.; Doucet, C. et al

Poster (2000, August)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailActivity and inhibition mechanism of coumarin-based derivatives as protease inhibitor
Pochet, L.; Doucet, C.; Dieu, M. et al

Poster (2000, June)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailEvaluation de la selectivité COX-1/COX-2 de drogues à visée anti-inflammatoire sur sang humain
De Leval, X.; Delarge, J.; Devel, P. et al

Poster (2000, May)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailConception, synthèse et évaluation pharmacologique de l’analogue pyridinique du nimésulide en tant qu’inhibiteur des cyclooxygénases
Julemont, F.; Neven, Ph.; De Leval, X. et al

Poster (2000, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailLe 6-(acetoxymethyl)-2-oxo-2H-1-benzopyrane-3-carboxylate de 3-chlorophényle agissant en tant qu’inhibiteur potentiel de l’invasion tumorale
Kempen, I.; Papapostolu, D.; Pochet, L. et al

Poster (2000, May)

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists
Dogne, J. M.; De Leval, X.; Neven, P. et al

Poster (2000, March 04)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailEvaluation of classical NSAIDs in a model of human whole blood assay
De Leval, X.; Delarge, J.; Devel, P. et al

Poster (2000, March 04)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailLes esters de l’acide 6-(acétoxyméthyl)-2-oxo-2H-1-benzopyrane-3-carboxylique en tant qu’agents antiinvasifs potentiels dans le traitement du cancer
Kempen, I.; Pochet, L.; Doucet, C. et al

Conference (2000, January 28)

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailCoumarinic derivatives as mechanism-based inhibitors of α-Chymotrypsin and human leucocyte elastase
Pochet, L.; Doucet, C.; Dive, Georges ULg et al

in Bioorganic & Medicinal Chemistry (2000), 8

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailProfile of nimesulide and nimesulide-L-lysine-β-cyclodextrin on chondrocyte metabolism
De Leval, X.; Dogne, J.-M.; Masereel, B. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of the effects of nimesulide and nimesulide-L-lysine on PGE2 production by COX-1 and COX-2 and on chondrocyte metabolism in vitro
De Leval, X.; Henrotin, Y.; Labasse, A. et al

in Pharmacy and Pharmacology Communications (2000), 6

Detailed reference viewed: 2 (2 ULg)
Peer Reviewed
See detailInhibition of cellular invasion by 3-chlorophenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-carboxylate
Kempen, I.; Pochet, L.; Papapostulu, D. et al

in Pflügers Archiv : European Journal of Physiology (2000), 439

Detailed reference viewed: 4 (3 ULg)
Peer Reviewed
See detailEvaluation of classical NSAIDs on COX-1 and COX-2 purified enzymes and prognosis of their effects on physiological responses
De Leval, X.; Henrotin, Y.; Masereel, B. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailCharacterization of antiplatelet activity of ticlopidine and acetylsalicylic acid by PFA-100
Dogne, J.-M.; De Leval, X.; Neven, P. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 12 (0 ULg)